BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach
Reuters2026/08/16 01:53- BeyondSpring highlighted plinabulin as a late-stage immune modulator positioned for 2L/3L NSCLC, including post–PD-1/L1 progression.
- DUBLIN-3 Phase 3 (n=559) met its primary endpoint, showing OS HR 0.82; median OS 10.5 months vs 9.4 months.
- Trial data also showed PFS, ORR improvements; grade 4 neutropenia fell sharply, including 33.58% to 5.13% on day 8.
- Company outlined DUBLIN-4 confirmatory Phase 3 in non-squamous EGFR, ALK, ROS1, RET WT NSCLC post-immunotherapy; global N=442; primary endpoint OS.
- Study 303 in post-ICI metastatic NSCLC (n=47) reported confirmed ORR 18.2%; median PFS 7.0 months; 24-month OS 58%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan’s Katayama: Confirmed with Bessent that continued, coordinated action on FX is needed
NTT Docomo Ventures takes stake in single-seat EV startup KG Motors
Renowned tech investor Gavin Baker: Data centers are creating a large number of high-paying blue-collar jobs
Baker believes that the construction of data centers can boost tax revenues in small towns and create high-paying blue-collar jobs. He also points out that the low natural gas prices in the United States provide a manufacturing cost advantage. He stated, "Learning trades like electrician, plumber, or HVAC technician now can earn you astonishing incomes, which in some cases might even surpass the net present value of going to college."
StrategX Elements extends non-brokered private placement deadline to Sept. 30, 2026
Crypto prices
More
